Protocol for risk stratification of ischemic events and optimized individualized treatment
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit preparation of an individualized assessment of ischemic event risk and individualized treatment of a subject.
1. A method of preparing an individualized ischemic event risk assessment, the method comprising:
determining for a first blood sample portion obtained from a subject a first clot characteristic related quantitative indication of hemostasis of the first blood sample portion;
determining for the first blood sample portion obtained from the subject a first enzymatic related quantitative indication of hemostasis of the first blood sample portion; and
determining a parameter indicative of the risk of the subject having an ischemic event based upon the first clot characteristic related quantitative indication and the first enzymatic related quantitative indication.
2. The method of claim 1 , further comprising:
determining for a second blood sample portion obtained from the subject post in vivo administration of a hemostasis therapy a second clot characteristic related quantitative indication of hemostasis of the second blood sample portion;
optionally determining for the second blood sample portion obtained from the subject a second enzymatic related quantitative indication of hemostasis of the second blood sample portion; and
determining a parameter indicative of the risk of the subject having an ischemic event based upon the second clot characteristic related quantitative indication and the second enzymatic related quantitative indication and determining the efficacy of the hemostasis therapy for the subject based upon the parameter.
3. The method of claim 2 , wherein each of the first blood sample and the second blood sample are prepared including in vitro administration of an activator.
4. The method of claim 3 , comprising comparing the first and the second clot characteristic related quantitative indications of hemostasis to correlation data and determining a dosing parameter of the hemostasis therapy in view of the correlation data.
5. The method of claim 1 , wherein the quantitative indication comprises one of initial clot formation, clot strength, clot elasticity, rate of clot formation or rate of clot lysis.